Partner Maria Raptis and associates Michael Frese, Marta Navarro Hernández and Julia Zhu discuss the Multilateral Pharmaceutical Merger Task Force, launched in 2021 by enforcement authorities in North America and Europe to update their approaches to analyzing the effects of pharmaceutical mergers. The authors focus on recent developments regarding the sufficiency of existing theories of harm, legal standards and remedies, which the task force has been evaluating.
The Guide to Life Sciences (Merger Control: Substantive Issues)
Global Competition Review